Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate

GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) support further development of polatuzumab vedotin (anti-CD79b ADC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

354Background: Each year more than 90,000 cases of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are expected in the US. The standard of care includes immuno-chemotherapy with alkylating agents in combination with an anti-CD20 monoclonal antibody, in addition to targeted therapies such as Bruton’s tyrosine kinase inhibitors. While immuno-chemotherapy regimens are initially effective in inducing responses, most patients inevitably relapse and the same therapies show decreasing efficacy with repeated administration. In recent years, CD37 has emerged as a new therapeutic target for B-cell malignancie...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) III Source Type: research
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This report concerns the effect of GA101 on Ca2+ signaling and its involvement in the direct cell death induced by GA101. We reveal that GA101 triggered an intracellular Ca2+ increase by mobilizing intracellular Ca2+ stores and activating Orai1-dependent Ca2+ influx in non-Hodgkin lymphoma cell lines and primary B-Cell Chronic Lymphocytic Leukemia (B-CLL) cells. According to the cell type, Ca2+ was mobilized from two distinct intracellular compartments. In Raji, BL2, and B-CLL cells, GA101 induced a Ca2+ release from lysosomes, leading to the subsequent lysosomal membrane permeabilization and cell death. Inhibition of this...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in western countries, accounting for approximately one quarter of all leukemias and Non-Hodgkin lymphoma (NHL) caused an estimated 200,000 cancer deaths worldwide in 2014. More than 90,000 cases of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are expected in the US each year. Immuno-chemotherapy using anti-CD20 monoclonal antibodies (mAb) in combination with DNA alkylating agents is the front-line therapy of CLL and NHL.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Source Type: research
CONCLUSION: Progression of CLL, AML, and NHL was associated with higher health care costs over a 12-month period. Delaying cancer progression resulted in a substantial cost reduction in patients with all three cancer types. IMPLICATIONS FOR PRACTICE: Data on the rates and incremental health care costs of disease progression in patients with hematologic malignancies are lacking. This study estimated the incremental costs of disease progression in patients diagnosed with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma and compared health care costs in patients with and without evidence o...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H FowlerSummaryBackgroundTherapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.Methods...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Authors: Chabannon C, Bouabdallah R, Fürst S, Granata A, Saillard C, Vey N, Mokart D, Fougereau E, Lemarie C, Mfarrej B, Blaise D, Calmels B Abstract CAR-T cells are genetically modified human lymphocytes and gene therapy medicinal products. They are developed to treat cancers that express a membrane antigen targeted by the CAR. The FDA approved the two first-in-class medicinal products in 2017 and EMA in August 2018; both are autologous CAR-T cells targeting CD19 that is expressed at the surface of normal B-cells throughout their differentiation, and on B-cell lymphoid malignancies. Clinical efficacy was demo...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
In conclusion, 96.5% of patients with hematologic malignancies have adequate tissue for comprehensive genomic profiling. Most patients had unique molecular signatures, and 75% had alterations that may be pharmacologically tractable with gene- or immune-targeted agents.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alte...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Overuse, Costs, and Utilization of Health Services Source Type: research
IntroductionLymphoma patients are at increased risk of thromboembolic events (TE), however, thromboprophylaxis in these patients is largely under utilized. Actual guidelines recommend different models for thromboembolic risk estimation in cancer patients. Proposed models are of limited use in lymphoma patients as their development is not based on specific characteristics for this patient population. Previously, we developed and internally validated a simple model, based on individual clinical and laboratory patient characteristics that would classify lymphoma patients at risk for a TE. The variables independently associate...
Source: Blood - Category: Hematology Authors: Tags: 331. Pathophysiology of Thrombosis: Cancer- and Children-Associated Thrombosis Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals | Rituxan